EAU 2017: Semi-ecologic, nationwide, population-based study of GnRH agonists, orchiectomy and risk of cardiovascular disease
London, England (UroToday.com) At the EAU 2017 annual congress’ advanced prostate cancer poster session, Dr. Stattin and colleagues from Sweden presented their population-based cohort study assessing risks of cardiovascular disease (CVD) among men receiving gonadotropic releasing hormone agonists (GnRHa) or bilateral simple orchiectomy for prostate cancer.
EAU 2017: 4th ESO Prostate Cancer Observatory: The Urologists Perspective
Dr. Tilki delivered the “Urologist’s Perspective on Surgery” at this morning’s EAU 2017 4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months session, focusing on salvage lymph node dissection (SLND) and PSMA imaging’s role for salvage treatment. Indeed, this is an expanding field with Dr. Tilki opening with a quote from her colleague in Belgium, Dr. Joniau: “It’s a bit like going from an old black and white TV to a large 3-D full color screen – you just see more than we used to see.”
EAU 2017: Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series
London, England (UroToday.com) Long-term updated outcomes help us understand the natural history of a disease with a long clinical course. The authors utilize their multi-institutional database to explore the 20-year outcomes for surgically-treated high-risk prostate cancer (HRPCa) patients.
EAU 2017: Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy
London, England (UroToday.com) With the increasing use of MRI prior to the formal diagnosis of prostate cancer, many patients often have a fusion biopsy prior to definitive treatment. In this study, the authors assess whether the use of images from an MRI/US fusion biopsy, in which 3D-mapping is completed, during Robot-assisted radical prostatectomy (RARP) affect surgical outcomes.
EAU 2017: 4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months
The “4th ESO Prostate Cancer Observatory: Innovation and Care in the Next 12 Months” was a standing-room only crowd with an international panel of experts highlighting important findings in prostate cancer research in 2016, and prognosticating what is to come in 2017.